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The successful enantioseparation of axially chiral amino acid derivatives containing a 
cyclohexylidene moiety on an analytical and semipreparative scale was achieved for the 
first time by HPLC using polysaccharide-based chiral stationary phases. Racemic methyl 
N-benzoylamino esters, easily obtained by methanolysis of the corresponding 5(4H)-
oxazolones, were subjected to chiral HPLC resolution using chiral stationary phases 
based on immobilized 3,5-dimethylphenylcarbamate derivatives of amylose (Chiralpak

IA column) or cellulose (Chiralpak

 IB column). The behaviour of both selectors under
different elution conditions was evaluated and compared. The amylose column showed 
better performance than the cellulose column for all enantiomers tested. 
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The semipreparative resolution of axially chiral amino acid derivatives with different 
side chains has been achieved on a 250 mm × 20 mm ID Chiralpak

 IA column using
the appropriate mixture of n-hexane/chlorofom/ethanol as eluent by successive 
injections of a solution of the sample in chloroform. Using this protocol up to 120 mg of 
each enantiomer of the corresponding axially chiral amino acid derivative were obtained 
from 300 mg of racemate. [(Sa)-2a, 105 mg; (Ra)-2a, 60 mg, [(Sa)-2b, 105 mg; (Ra)-2b, 
90 mg, [(Sa)- 2c, 120 mg; (Ra)-2c, 100 mg]. 
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1. Introduction40 
41 
42 
43 
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45 
46 
-Amino acids are considered to be amongst the most important building blocks 
in chemistry. Apart from being the structural subunits of proteins, peptides and many 
secondary metabolites they are versatile chiral starting materials for the synthesis of 
peptides, alkaloids, antibiotics and more complex molecules with biological activities 
[1-3]. Amino acids have also been used as chiral auxiliaries, ligands and catalysts in 
asymmetric synthesis [4-8]. 47 
The design and synthesis of new -amino acids with unusual structural features 48 
that can provide peptides with improved biological properties, more versatile chiral 49 
*Manuscript
Click here to view linked References
50 synthons or catalysts capable of inducing higher asymmetry is a subject of 
continued interest [9-14]. 51 
52 
53 
54 
55 
56 
In most of the newly designed chiral amino acids, chirality relies on the presence 
of one or more a stereogenic atoms. Chirality may arise from another type of molecular 
asymmetry, namely the presence of a chiral axis. In this context, atropoisomeric -
amino acids with a biaryl axis in their structure have been synthesised [15-19] and 
resolved [20-21], and the behaviour of model peptides that incorporate these unusual 
amino acids has been studied in detail . [22-27]  57 
58 
59 
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In the course of our research we prepared racemic (4-substituted 
cyclohexylidene)glycines (Figure 1), another family of axially chiral amino acids, which 
can be considered as elongated structural analogues of parent amino acids, and small 
peptides derived from them  [28-30] We became interested in the development of a 
practical procedure for the isolation of these axially chiral amino acids in 
enantiomerically pure form.  63 
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High-performance liquid chromatography using chiral stationary phases is a 
powerful tool for the direct analysis of enantiomers. High-performance liquid 
chromatography on a semipreparative scale is considered to be one of the most efficient 
approaches to obtain small amounts of enantiomerically pure compounds in a reasonable 
time  [31-33] which is of paramount importance in pharmaceutical research and drug 
development. Different protocols to perform the enantiomeric separation of chiral 
nonproteinogenic amino acids with stereogenic atoms by high-performance liquid 
chromatography have been described [34]. As far as axially chiral amino acids are 
concerned, the analytical resolution of atropoisomeric -amino acid Bin has been 
performed on a -cyclodextrin-based chiral stationary phase, ChiralDex [35].  
Nevertheless, to the best of our knowledge work has not been published on the 
development of enantioselective chromatographic protocols for the quantitative 
determination and preparative resolution of axially chiral amino acids containing a 
cyclohexylidene moiety [36].  77 
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Our efforts were focused on developing chromatographic protocols to perform 
the enantioseparation of axially chiral (4-substituted cyclohexylidene)glycine derivatives 
on an analytical and semipreparative scale by high performance liquid chromatography 
using chiral stationary phases. Among the different chiral stationary phases available, 
those based on polysaccharides are exceptionally versatile for the analytical separation 
of many different chiral compounds [37]. In the work described here, chiral stationary 
phases (CSPs) based on immobilized amylose and cellulose were chosen since they are 
particularly useful for preparative-scale enantioseparation due to the combination of 
excellent chiral recognition properties, compatibility with organic solvents and high 
loading capacity [38, 39].  Moreover, these stationary phases are commercially 
available. 88 
89 
2. Experimental90 
91 
2.1. Materials and methods (Chemicals and reagents) 92 
93 
94 
95 
96 
97 
98 
99 
All the reagents and solvents were reagent grade and were used without further 
purification unless otherwise specified. n-Hexane, isopropanol, ethanol, acetone and 
chloroform used for HLPC separations were chromoscan grade from LabScan (Avantor 
Performance Materials Poland S.A, Gliwice, Poland). Reactions were magnetically 
stirred and monitored by thin-layer chromatography (TLC) on 0.25-mm silica gel plates. 
UV light, p-anisaldehyde, ninhydrin and phosphomolybdic acid sprays were applied for 
visualization. 5(4H)-Oxazolones 1a, 1b and 1c were prepared according to our 
previously described procedure [29]. 100 
101 
2.2. Instrumentation 102 
103 
104 
105 
106 
107 
108 
109 
110 
111 
112 
HPLC separations were carried out on a Waters HPLC system (Waters 
Corporation, Milford, USA) consisting of an M-600 low-pressure gradient pump, an M- 
2996 photodiode array detector and an M-2487 dual wavelength absorbance detector, to 
monitor analytical and preparative separations, respectively. The chromatographic data 
were acquired and processed with Millennium

 chromatography manager software 
(Waters). A rheodine 7125 syringe-loading sample injector was equipped with 20- and 
500-L loops for analytical or semipreparative chromatography. Commercially available 
polysaccharide chiral stationary phases based on amylose tris(3,5-
dimethylphenylcarbamate), Chiralpak

 IA column, and cellulose tris(3,5-
dimethylphenylcarbamate), Chiralpak

 IB column (Chiral Technologies Europe, Illkirch 
Cedex, France), were used.  113 
The HPLC analytical assays were carried out operating under isocratic conditions 114 
at room temperature on Chiralpak

 IA and Chiralpak

 IB 250 × 4.6 mm ID columns.115 
Different binary and ternary mixtures of solvents were used as eluents. Samples were 116 
manually injected. The flow rate was 1 mL/min. The analyte concentration in injected 117 
solutions was 5 mg/mL and the injection volume was 5 L. Detection was performed at 118 
multiple wavelengths for each compound. The capacity (k'), selectivity () and 119 
resolution (Rs) factors were calculated according to the equations k' = (tr – t0)/t0,  = 120 
k'2/k'1, Rs = 2(t2 – t1)/(w2 + w1). Subscripts 1 and 2 refer to the first and second eluted 121 
enantiomer, respectively, tr (r = 1, 2) are their retention times, and w1 and w2 denote 122 
their baseline peak widths; t0 is the dead time. 123 
The HPLC semipreparative resolution of compound 2a–c was carried out 124 
operating under isocratic conditions at room temperature on a 250 × 20 mm ID 125 
Chiralpak

 IA column. A ternary mixture of n-hexane/ethanol/chloroform was used as126 
the eluent. Injections and collections were made manually. The flow rate was 18 127 
mL/min for compound 2a and 16 mL/min for compounds 2b and 2c. The wavelength for 128 
UV detection was 280, 290 and 265 nm for compounds 2a, 2b and 2c, respectively. 129 
Both the column loading capacity, Ws (defined as the maximum sample mass that the 130 
column can hold) and the optimum sample concentration were calculated in each case 131 
for the analytical 250 × 4.6 mm ID Chiralpak

 IA column by injecting increasing132 
amounts of sample at different concentrations.  133 
134 Melting points were recorded on a Gallenkamp capillary melting point apparatus 
(Weiss-Gallenkamp, Loughborough, United kindom) in open capillaries and are not 135 
corrected. 136 
137 
138 
Optical rotations were measured on a Jasco P-1020 digital polarimeter from 
(Jasco Corporation, Tokio, Japan). []D values are given in units of 10
–1
 deg·cm·g
–1
 and 
concentrations are given in g/100 mL.139 
140 
141 
FTIR spectra were recorded as nujol dispersions on NaCl plates or as KBr pellets 
using a Thermo Nicolet Avatar 360 FT-IR spectrometer (Thermo Fischer Scientific, 
Waltham, Massachusetts, USA), max values expressed in cm
–1 
are given for the main142 
absorption bands. 143 
1
H NMR and 
13
C NMR spectra were acquired on a Bruker AV-500 spectrometer, 144 
145 
146 
147 
148 
149 
a Bruker AV-400 spectrometer or a Bruker AV-300 spectrometer (Bruker-Biospin, 
Rheinstetten, Germany) operating at 500, 400 or 300 MHz for 
1
H NMR and 125, 100 or 
75 MHz for 
13
C NMR at room temperature using a 5-mm probe unless stated otherwise. 
The chemical shifts ( )are reported in parts per million from tetramethylsilane with the 
solvent resonance as the internal standard [40]. [39] The following abbreviations for 
splitting patterns are reported as s (singlet), d (doublet), m (multiplet), ddd (doublet of 150 
doublet of doublets) and br (broad). Coupling constants (J) are quoted in Hertz. 
13
C151 
Attached Proton Test (APT) spectra were taken to determine the types of carbon signals. 152 
High resolution mass spectra were recorded using a Bruker Daltonics MicroToF-153 
Q instrument (Bruker Daltonics, Billerica, Massachusetts, USA) from methanolic 154 
solutions using the positive electrospray ionization mode (ESI+).  155 
156 
157 
158 
2.3. General procedure for the synthesis and resolution of axially chiral amino acid 159 
derivatives rac-2a, rac-2b and rac-2c 160 
161 
162 
163 
164 
2.3.1. Methyl 2-benzamido-2-(4-phenylcyclohexylidene)acetate (rac-2a).  
165 
166 
167 
168 
Yield 670 mg (97%), IR absorptions (nujol) max 3268, 1722; 1637, 
169 
1
H NMR (400 MHz, CDCl3):  = 1.66–1.78 (m, 2H), 2.00–2.26 (m, 4H), 2.75–2.85 (m, 170 
2H), 3.70 (ddd, 1H, J = 14.0, 5.6, 3.2 Hz), 3.79 (s, 3H), 7.17–7.23 (m, 3H), 7.28–7.32 171 
(m, 2H), 7.41 (brs, 1H), 7.45–7.20 (m, 2H), 7.52–7.57 (m, 1H), 7.85–7.88 (m, 2H), 13C172 
NMR (100 MHz, CDCl3)  = 30.2 (CH2), 31.4 (CH2), 34.3 (CH2), 34.8 (CH2), 44.0 173 
(CH), 52.0 (CH3), 118.6 (C), 126.2 (CH), 126.7 (CH), 127.2 (CH), 128.4 (CH), 128.6 174 
(CH), 131.9 (CH), 133.8 (C), 145.8 (C), 149.7 (C), 165.5 (C), 166.1 (C); HRMS (FAB
+
)175 
calcd for C22H23NO3Na (MNa
+
) 372.1570; found 372.1567.176 
177 
178 
179 
180 
181 
182 
183 
184 
185 
 300 mg of rac-2a dissolved in CHCl3 (12 mL) were resolved by successive injections of 
500 L of solution on a 250 × 20 mm ID Chiralpak IA column and using a ternary 
mixture n-Hx/EtOH/CHCl3 (86/7/7) as the eluent (flow rate: 18 mL/min). A total of 24 
injections were performed, with one injection performed every 12 min. Four separate 
fractions were collected. The first, second, third and fourth fractions contained, 
respectively, 100/0 (105 mg), 85/15 (28 mg), 4/96 (72 mg) and 0/100 (60 mg) mixtures 
of (Sa)-2a and (Ra)-2a. (Sa)-2a: White solid, m. p. = 189.8 ºC; []D25 = 45.5 (c 0.75, 
CHCl3). (Ra)-2a: White solid, m. p. = 189.6 ºC; []
D
25 = –45.4 (c 0.70, CHCl3). 
Spectroscopic data for (Sa)-2a and (Ra)-2a were identical to those given above for the 
racemic compound. 186 
187 
188 
189 
190 
191 
192 
193 
194 
195 
2.3.2. Methyl 2-benzamido-2-(4-methylcyclohexylidene)acetate (rac-2b). Yield 645 mg 
(98%), IR absorptions (nujol) max 3268, 1722; 1638, 
196 
1
H NMR (400 MHz, CDCl3):  = 0.89 (d, 3H, J = 6.6 Hz), 1.11 (ddd, 1H, J = 13.0, 3.6, 197 
3.6 Hz), 1.17 (ddd, 1H, J = 13.0, 3.6, 3.6 Hz), 1.56–1.68 (m, 1H), 1.76–1.87 (m, 2H), 198 
1.97 (ddd, 1H, J = 13.5, 13.5, 4.5 Hz), 2.06 (ddd, 1H, J = 13.5, 13.5, 4.3 Hz), 2.62 (ddd, 199 
1H, J = 14.0, 5.7, 3.4 Hz), 3.41 (ddd, 1H, J = 14.0, 5.5, 3.4 Hz), 3.74 (s, 3H), 7.38–7.43 200 
(m, 2H), 7.46–7.42 (m, 1H), 7.58 (brs, 1H), 7.81–7.85 (m, 2H); 13C NMR (100 MHz,201 
CDCl3)  = 21.5 (CH3), 29.7 (CH2), 30.9 (CH2), 32.0 (CH), 35.3 (CH2), 35.7 (CH2), 51.8 202 
(CH3), 118.5 (C), 127.2 (CH), 128.5 (CH), 131.7 (CH), 133.8 (C), 150.7 (C), 165.6 (C), 203 
166.3 (C); HRMS (FAB
+
) calcd for C17H21NO3Na (MNa
+
) 310.1414; found 310.1412.204 
205 
206 
207 
208 
209 
210 
211 
212 
213 
214 
300 mg of rac-2b dissolved in CHCl3 (2 mL) were resolved by successive injections of 
150 L of solution on a 250 × 20 mm ID Chiralpak IA column and using a ternary 
mixture n-Hx/EtOH/CHCl3 (84/4/12) as the eluent (flow rate: 16 mL/min). A total of 13 
injections were performed, with one injection performed every 20 min. Four separate 
fractions were collected. The first, second, third and fourth fractions contained, 
respectively, 98.5/1.5 (105 mg), 85/15 (14 mg), 6/94 (41 mg) and 0/100 (90 mg) 
mixtures of (Sa)-2b and (Ra)-2b. (Sa)-2b: White solid, m. p. = 167–168 ºC; []D25 = 15.8 
(c 0.59, CHCl3).(Ra)-2b: White solid, m. p. = 167–168 ºC; []
D
25 = –15.8 (c 0.55, 
CHCl3). Spectroscopic data for (Sa)-2b and (Ra)-2b were identical to those given above 
for the racemic compound. 
215 
216 
217 
218 
219 
220 
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222 
223 
224 
2.3.3. Methyl 2-benzamido-2-(4-tert-butylcyclohexylidene)acetate (rac-2c). Yield 545 
mg (95%), IR absorptions (nujol) max 3231, 1719; 1635, 
225 
H NMR (400 MHz, CDCl3):  = 0.85 (s, 9H), 1.16–1.29 (m, 3H), 1.87–2.04 (m, 4H), 226 
2.70 (ddd, 1H, J = 13.6, 5.3, 2.9 Hz), 3.54 (ddd, 1H, J = 13.6, 5.1, 2.6 Hz), 3.75 (s, 3H), 227 
7.40–7.45 (m, 2H), 7.48–7.54 (m, 2H), 7.81–7.85 (m, 2H); 13C NMR (100 MHz, CDCl3)228 
 = 27.6 (CH3), 28.0 (CH2), 28.4 (CH2), 30.3 (CH2), 31.6 (CH2), 32.5 (C), 47.6 (CH), 229 
51.9 (CH3), 118.2 (C), 127.3 (CH), 128.6 (CH), 131.7 (CH), 133.9 (C), 151.3 (C), 165.7 230 
(C), 166.4 (C); HRMS (FAB
+
) calcd for C20H27NO3Na (MNa
+
) 352.1883; found231 
352.1851. 232 
233 
234 
235 
236 
237 
238 
239 
240 
241 
300 mg of rac-2c dissolved in CHCl3 (4 mL) were resolved by successive injections of 
200 L of solution on a 250 × 20 mm ID Chiralpak IA column and using a ternary 
mixture n-Hx/EtOH/CHCl3 (92/4/4) as the eluent (flow rate: 16 mL/min). A total of 20 
injections were performed, with one injection performed every 13 min. Four separate 
fractions were collected. The first, second, third and fourth fractions contained, 
respectively, 100/0 (120 mg), 82/18 (32 mg), 3/97 (40 mg) and 0/100 (100 mg) mixtures 
of (Sa)-2c and (Ra)-2c. (Sa)-2c: White solid, m. p. = 83 ºC; []D25 = 10.2 (c 0.54, 
CHCl3). (Ra)-2c: White solid, m. p. = 82–83 ºC; []
D
25 = –10.8 (c 0.75, CHCl3). 
Spectroscopic data for (Sa)-2c and (Ra)-2c were identical to those given above for the 
racemic compound. 242 
243 
2.4. General procedure for the saponification of axially chiral amino acid derivatives 244 
2a, 2b and 2c 245 
A mixture of the corresponding racemic or enantiomerically pure N-benzoyl 246 
amino ester 2a–c (1 mmol) in 4% ethanolic potassium hydroxide (12 mL) was stirred at 247 
room temperature for one day. After concentration of the solution in vacuo, water was 248 
added and the aqueous phase was washed with diethyl ether. The aqueous layer was 249 
acidified with 1N hydrochloric acid and then extracted with dichloromethane. 250 
Concentration in vacuo of the organic layer resulted in the appearance of a pale yellow 251 
solid, which was washed with a small portion of diethyl ether to afford pure samples of 252 
the corresponding racemic or enantiomerically pure N-benzoyl amino acid 3a–c. Yields 253 
were almost quantitative for 3a and 3c and about 90% for 3b.  254 
255 
2.4.1. 2-Benzamido-2-(4-phenylcyclohexylidene)acetic acid (rac-3a). White solid, IR 256 
absorptions (KBr) max 3303, 1713; 1647, 
1
H NMR (400 MHz, DMSO-d6):  = 1.42–257 
1.63 (m, 2H), 1.90–2.01 (m, 2H), 2.03–2.07 (m, 2H), 2.77–2.83 (m, 2H), 3.53 (brd, 1H, 258 
J = 13.06 Hz), 7.15–7.31 (m, 5H), 7.46–7.57 (m, 3H), 7.93–7.96 (m, 2H), 9.70 (s, 1H), 259 
12.50 (brs, 1H); 
13
C NMR (100 MHz, DMSO-d6)  = 29.4 (CH2), 30.4 (CH2), 34.2260 
(CH2), 34.6 (CH2), 43.1 (CH), 121.3 (C), 126.20 (CH), 126.6 (CH), 127.5 (CH), 128.2 261 
(CH), 128.3 (CH), 131.4 (CH), 133.7 (C), 145.1 (C), 146.1 (C), 165.6 (C), 166.3 (C); 262 
HRMS (FAB
+
) calcd for C21H21NO3Na (MNa
+
) 358.1414; found 358.1389.263 
(Sa)-3a: White solid, m. p. (dec) = 195–200 ºC; []D25 = –9.1 (c 0.33, CH3OH). (Ra)-3a:264 
White solid, m. p. (dec) = 195–200 ºC; []D25 = 8.9 (c 0.32, CH3OH). Spectroscopic data265 
for (Sa)-3a and (Ra)-3a were identical to those given above for the racemic compound. 266 
267 
2.4.2. 2-Benzamido-2-(4-methylcyclohexylidene)acetic acid (rac-3b). White solid, IR 268 
absorptions (KBr) max 3270, 1693; 1648, 
1
H NMR (400 MHz, DMSO-d6):  = 0.88 (d,269 
3H, J = 6.4 Hz), 0.97–1.12 (m, 2H), 1.55–1.65 (m, 1H), 1.73–1.83 (m, 2H), 1.88 (ddd, 270 
1H, J = 13.4, 13.4, 4.4 Hz), 1.98 (ddd, 1H, J = 13.4, 13.4, 3.6 Hz), 2.58–2.64 (m, 1H), 271 
3.28–3.36 (m, 1H), 7.45–7.50 (m, 2H), 7.53–7.57 (m, 1H), 7.88–7.92 (m, 2H), 9.60 (s, 272 
1H), 12.27 (brs, 1H); 
13
C NMR (100 MHz, DMSO-d6)  = 21.7 (CH3), 29.1 (CH2), 30.1273 
(CH2), 31.6 (CH), 35.2 (CH2), 35.6 (CH2), 120.8 (C), 127.6 (CH), 128.4 (CH), 131.5 274 
(CH), 133.8 (C), 146.4 (C), 165.7 (C), 166.4 (C); HRMS (FAB
+
) calcd for275 
C16H19NO3Na (MNa
+
) 296.1257; found 296.1262.276 
(Sa)-3b: White solid, m. p. = 216–220 ºC; []D25 = –12.8 (c 0.87, CH3OH). (Ra)-3b:277 
White solid, m. p. = 215–218 ºC; []D25 = 12.6 (c 0.87, CH3OH). Spectroscopic data for278 
(Sa)-3b and (Ra)-3b were identical to those given above for the racemic compound. 279 
280 
2.4.3. 2-Benzamido-2-(4-tert-butylcyclohexylidene)acetic acid (rac-3c). White solid, IR 281 
absorptions (KBr) max 3422, 1732; 1637, 
1
H NMR (400 MHz, DMSO-d6):  = 0.85 (s,282 
9H), 1.03–1.18 (m, 2H), 1.22–1.30 (m, 1H), 1.79–1.99 (m, 4H), 2.70–2.74 (m, 1H), 283 
3.42–3.46 (m, 1H), 7.46–7.50 (m, 2H), 7.53–7.58 (m, 1H), 7.90–7.94 (m, 2H), 9.60 (s, 284 
1H), 12.30 (brs, 1H); 
13
C NMR (100 MHz, DMSO-d6)  = 27.2 (CH3), 27.6 (CH2), 28.1285 
(CH2), 29.4 (CH2), 30.4 (CH2), 32.0 (C), 46.8 (CH), 120.4 (C), 127.4 (CH), 128.1 (CH), 286 
131.3 (CH), 133.6 (C), 146.4 (C), 165.4 (C), 166.2 (C); HRMS (FAB
+
) calcd for287 
C19H25NO3Na (MNa
+
) 338.1727; found 338.1737.288 
(Sa)-3c: White solid, m. p. = 184–186 ºC; []D25 = –11.3 (c 0.39, CH3OH). (Ra)-3c:289 
White solid, m. p. = 185–188 ºC; []D25 = –11.0 (c 0.36, CH3OH). Spectroscopic data290 
for (Sa)-3b and (Ra)-3b were identical to those given above for the racemic compound. 291 
292 
2.5 General procedure for the synthesis of dipeptides 4a, 4b and 4c 293 
294 
Enantio-enriched N-benzoyl amino acid 3a–c (0.3 mmol) from preparative HPLC 295 
and N-hydroxysuccinimide (HOSu) (35 mg, 0.3 mmol) were dissolved in dry 296 
dichloromethane (5 mL) under an inert atmosphere. The mixture was cooled to 0 ºC and 297 
N,N'-dicyclohexylcarbodiimide (DCC) (62 mg, 0.4 mmol) was added. The mixture was 298 
stirred at 0 ºC for 90 min and (S)-phenylalanine cyclohexylamide (53.8 mg, 0.3 mmol) 299 
was added. The reaction mixture was stirred at room temperature for 24 h. The resulting 300 
white solid was filtered off. The solution was diluted with dichloromethane and washed 301 
successively with 5% aqueous potassium bisulfate, 5% aqueous sodium bicarbonate and 302 
brine. The organic layer was dried over anhydrous magnesium sulfate and evaporated to 303 
dryness. The resulting dipeptides were purified by silica gel column chromatography 304 
using hexane/ethyl acetate (1:1) as eluent (yield about 20%). Spectroscopic data for the 305 
obtained enantio-enriched dipeptides were compared to those previously reported in the 306 
literature [29] in order to assign unambiguously the configuration of N-benzoylamino 307 
acids and esters. 308 
309 
3. Results and discussion310 
311 
3.1. Synthesis 312 
313 
314 
315 
316 
317 
318 
319 
320 
321 
322 
Starting 2-phenyl-4-(4-substitutedcyclohexylidene)oxazol-5(4H)-ones 1a–c were 
prepared by condensation of hippuric acid and the corresponding 4-
substitutedcyclohexanone according to the reported procedure [29]. Smooth 
methanolysis of the ring with sodium methoxide in methanol led to the corresponding 
methyl 2-benzamido-2-(4-substitutedcyclohexylidene)acetates 2a–c as racemic 
mixtures, which were fully separated by HPLC with chiral stationary phases as detailed 
below. Racemic, enantioenriched or enantiomerically pure benzamido esters 2a–c were 
treated with 4% alcoholic potassium hydroxide solution to give benzamido acids 3a–c as 
racemic, enantioenriched or enantiomerically pure compounds. (Figure 1). 
323 
324 
3.2. Analytical enantioseparation 325 
326 
327 
328 
329 
330 
331 
332 
333 
334 
Enantioseparation of methyl 2-benzamido-2-(4-substitutedcyclohexylidene) 
acetates 2a–c using 250 × 4.6 mm ID columns containing chiral stationary phases based 
on immobilized 3,5-dimethylphenylcarbamate derivatives of amylose or cellulose, 
namely Chiralpak

 IA [41] and Chiralpak

 IB [42] , were first examined at the analytical 
level. The capacity (k'), selectivity () and resolution (Rs) factors for each column in the 
enantioseparation of all compounds using mixtures of n-hexane/2-propanol as the eluent 
were determined. The separation factor and resolution for analytes 2a–2c in the 
optimized mobile phase composition are shown in  Figure 2. 
335 
All enantiomers were resolved in at least in one of the two chiral columns but 336 
significant peak tailing was observed. As the primary cause of peak tailing is the 337 
occurrence of more than one mechanism of analyte retention, replacement of the 2-338 
propanol in the eluting mixture by acetone was tested in order to minimize peak tailing. 339 
This change did not have a positive effect on enantioseparation of any of the tested 340 
analytes for either the amylose or the cellulose-based phases, as shown in Figure 1 341 
Figure 2, with the optimized mobile phase composition. In fact, compound 2c was not 342 
separated on the Chiralpak

 IB column with this mobile phase.343 
As can be seen form Figure 1 Figure 2, in most cases the Chiralpak

 IA column344 
provides better selectivity and resolution than the Chiralpak

 IB column for analytes345 
2a–c with both mobile phases with the optimized compositions. The former column was 346 
selected for further optimization to extend the study to the preparative-scale 347 
enantioseparation.  348 
Another cause of peak tailing is low solubility of the analyte in the mobile phase 349 
and, as a consequence, changes in the mobile phase composition to improve the sample 350 
solubility were investigated (Table 1).  351 
352 
353 
354 
355 
356 
357 
358 
359 
360 
361 
Replacement of the 2-propanol in the eluting mixture by ethanol, which has a 
more polar character, usually increases analyte solubility and decreases peak tailing. 
However, this change had a different effect in the chiral recognition ability of the 
column for each analyte, because different alcohol modifiers not only modify the analyte 
solubility but can also cause structural differences in the helical structure of the polymer 
and as a consequence changes in its recognition ability [43, 44]. As can be seen from the 
results in Table 1, elution with mixtures of n-hexane/ethanol achieved enantioseparation 
in all cases but, whereas for compound 2a the resolution increased to almost complete 
baseline separation of peaks [n-hexane/ethanol 92/8 and 90/10 (v/v)], for compounds 2b 
and 2c resolution was not improved when compared to elution with mixtures of 
hexane/2-propanol.  362 
363 
364 
365 
366 
367 
368 
369 
370 
371 
372 
373 
374 
375 
376 
377 
378 
379 
In order to enhance the solubility of analytes and increase the loading capacity of the 
column for the work at the semipreparative scale the addition of chloroform as a third 
component to the eluting mixture was evaluated. On the other hand the lower viscosity 
of ethanol in comparison to 2-propanol causes a lower column pressure, which is 
beneficial for the work at the semipreparative scale. The enantioseparation using ternary 
mixtures of n-hexane/ethanol/chloroform was subsequently studied. The presence of a 
small percentage of chloroform in the mobile phase led to a substantial enhancement in 
the sample solubility and increased substantially the loading capacity of the column 
while providing selectivity and resolution factors that allow enantioseparation at the 
semipreparative scale (Table 1). The optimized ternary mixtures n-hexane/ethanol/
chloroform as far as selectivity, resolution and analyte solubility is concerned were 
86/7/7 (v/v/v) for 2a (Rs = 2.36), 84/4/12 (v/v/v) for 2b (Rs = 1.62) and 92/4/4 (v/v/v) 
for 2c (Rs = 1.38). Figure 3 shows the chromatographic resolution of rac- 2a, rac-2b and 
rac-2c by analytical HPLC with optimized ternary mixtures. 
380 
381 
382 
383 
384 
385 
3.2. Semipreparative enantioseparation 386 
387 
One of the critical factors in preparative HPLC is the loading capacity. The value 388 
for this parameter should be one that allows a good compromise between the resolved 389 
amount of racemate per injection and the purity of the resolved enantiomers. In order to 390 
optimize the semipreparative enantioseparation, the column saturation capacity (Ws) was 391 
determined in an experimental approach starting from the previously determined elution 392 
conditions on the analytical column. Firstly, concentration overloading on the analytical 393 
column was achieved by injecting samples of increasing concentration under the same 394 
analytical conditions until the peaks remained resolved. Once concentration overloading 395 
had been ascertained, volume overloading can be determined in a similar way by 396 
increasing the injected volume of the samples. The chromatographic data obtained on 397 
working in an overload mode on the analytical column are shown in Table 2. 398 
Finally, an additional scale-up of the system from the analytical to the 399 
semipreparative column was necessary. The two parameters that must be scaled when 400 
moving from a column with a smaller i.d. to one with a larger i.d. are the flow rate and 401 
the injected volume, taking into account the fact that the ratio between their volumes is 402 
equal to the ratio between the square of their diameters.  403 
On working in an overload mode both in mass and volume, the capacity of the 404 
semipreparative column and the optimum concentration of the sample and injected 405 
volume were determined to be 12.5 mg (25 mg/mL, 500 L) for compound 2a, 22.5 mg 406 
(150 mg/mL, 150 L) for compound 2b and 15 mg (75 mg/mL, 200 L) for compound 407 
2c.  408 
409 
410 
411 
412 
413 
414 
415 
416 
417 
418 
419 
The semipreparative resolution of compounds 2a–c on a 250 mm × 20 mm ID 
Chiralpak

 IA column was achieved by successive injections of a solution of the sample 
in chloroform, 24 injections of 500 L for compound 2a, 13 injections of 150 L for 
compound 2b and 20 injections of 200 L for compound 2c. In order to enhance 
throughput, injections were partially overlapped and for each run four separate fractions 
were collected and combined with equivalent fractions. The combined fractions were 
concentrated and reinjected onto the analytical chiral column to determine their 
enantiomeric purity. The profile of the chromatogram obtained for the analytical column 
operating in an overload mode to establish the loading capacity of the column is shown 
in  Figure 4 along with the chromatogram of the semipreparative resolution of compound 
2a. The corresponding analytical check of the four collected fractions in the resolution of 
compound 2a is shown in Figure 5.  420 
The first and the second eluted enantiomers were isolated in enantiomerically 421 
pure form in the first and the fourth fractions, respectively. The second and the third 422 
fractions contained mixtures enriched in either the first or the second eluted enantiomer. 423 
Taking into account the concentration of the sample and the injection volume for each 424 
analyte, 60–70 mg of each racemate were resolved per hour. Using this protocol 300 mg 425 
of each racemate was resolved. The recovered amount and the enantiomeric ratios of the 426 
different enantiomers in each fraction collected are shown in Table 3.  427 
428 
3.4. Absolute configuration determination 429 
430 
431 
432 
433 
434 
435 
436 
437 
438 
439 
440 
441 
In order to determine the absolute configuration of the resolved N-benzoylamino 
esters, partially resolved compounds were transformed into the corresponding free 
amino acids, namely N-benzoylamino acids 3a–c, by saponification with 4% alcoholic 
potassium hydroxide according to  Figure 1. The acids were then then coupled with (S)-
phenylalanine cyclohexylamide in the presence of N,N'-dicyclohexylcarbodiimide 
(DCC) and N-hydroxysuccinimide (HOSu) to give enriched mixtures in known 
compounds (Ra,S)-4a–c and (Sa,S)-4a–c (Figure 6), the stereochemistry of which had 
been previously assigned on the basis of X-ray diffraction experiments. [29] Comparison 
of the physical and spectroscopic data with those previously reported in the literature for 
the same compounds allowed us to unambiguously assign the Sa configuration to the 
first eluted N-benzoylamino ester and the Ra configuration to the more strongly retained 
N-benzoylamino ester. 442 
443 
4. Conclusions444 
445 
For the first time, efficient HPLC methods for the analytical and semipreparative 446 
resolution of axially chiral amino acid derivatives have been developed. The use of 447 
ternary mixtures of n-hexane/ethanol/chloroform as eluent and amylose tris(3,5-448 
449 
450 
451 
452 
453 
454 
455 
456 
dimethylphenylcarbamate) as the chiral selector allowed good baseline 
enantioseparations to be achieved at the analytical scale. The analytical method was 
successfully scaled up to semipreparative loadings and about 60–70 mg of each 
racemate were resolved per hour. Up to 120 mg of the axially chiral amino acid have 
been isolated in enantiomerically pure from 300 mg of the racemic mixture.  
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Figure and Scheme captions 617 
618 
Scheme 1. Fig. 1. Synthesis and structures of compounds 2a–c. 619 
620 
Fig. 1. Fig. 2.Separation factor () and resolution (Rs) for analytes 2a, 2b and 2c (left 621 
and right graphics, respectively) on 250 × 4.6 mm ID Chiralpak

 IA and Chiralpak

 IB622 
columns. Chromatographic conditions: injection volume: 5 μL, samples dissolved in 623 
chloroform, flow rate 1 mL/min; UV detection 220 nm. Mobile phase composition: A, 624 
n-Hx/2-PrOH 95/5 (v/v); B, n-Hx/2-PrOH 90/10 (v/v); C, n-Hx/2-PrOH 97/3 (v/v); D, n-625 
Hx/acetone 90/10 (v/v); E, n-Hx/acetone 95/5 (v/v). 626 
627 
Fig. 2. Fig. 3. Chromatograms for the enantioseparation of compounds 2a, 2b and 2c on 628 
a 250 × 4.6 mm ID Chiralpak

 IA column. (A) Mobile phase composition n-629 
Hx/EtOH/CHCl3 86/7/7 (v/v/v), flow rate: 1 mL/min; UV detection: 260 nm, 630 
chromatographic parameters: k' = 2.92, = 1.16, Rs = 2.36; (B) mobile phase 631 
composition n-Hx/EtOH/CHCl3 84/4/12 (v/v/v)), flow rate: 1 mL/min; UV detection: 632 
235 nm, chromatographic parameters: k' = 1.86, = 1.19, Rs = 1.62; (C) mobile phase 633 
composition n-Hx/EtOH/CHCl3 92/4/4 (v/v/v), flow rate: 1 mL/min; UV detection: 235 634 
nm, chromatographic parameters: k' = 3.15, = 1.13, Rs = 1.38. 635 
636 
Fig. 3. Fig. 4. (A) Chromatogram for the enantioseparation of compound 2a operating in 637 
an overload mode on a 4.6 × 20 mm ID Chiralpak

 IA column. Injection volume: 25 μL,638 
c = 25 mg/mL, flow rate, 1 mL/min; UV detection 280 nm, eluent n-Hx/EtOH/CHCl3 639 
86/7/7. (B) Semipreparative chromatogram for the enantioseparation of compound 2a on 640 
a 250 × 20 mm ID Chiralpak

 IA column. Injection volume: 500 μL, c = 25 mg/mL,641 
flow rate, 18 mL/min; UV detection 280 nm, eluent n-Hx/EtOH/CHCl3 86/7/7, repetitive 642 
injection every 12 min. 643 
644 
Fig. 4. Fig. 5. Analytical check of the fractions collected in the enantioseparation of 645 
compound 2a on a 250 × 4.6 mm ID Chiralpak

 IA column. Injection volume: 5 μL, c =646 
5 mg/mL, flow rate, 1 mL/min; UV detection 240 nm, eluent n-Hx/EtOH/CHCl3 86/7/7. 647 
(a) First fraction collected. (b) Second fraction collected. (c) Third fraction collected. (b) 648 
Fourth fraction collected. 649 
650 
Scheme 2. Fig. 6. Synthesis and structure of compounds 4a–c. DCC = N,N’-651 
dicyclohexylcarbodiimide, HOSu = N-hydroxysuccinimide. 652 
653 
654 
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Table 1  
Selected chromatographic data for the analytical HPLC resolution of amino acid 
derivatives rac-2a–c on Chiralpak IA using different mobile phases.a
Compound Eluent % (v/v) k'  Rs 
rac-2a n-Hx/2-PrOH 95/5 5.11 1.24 1.98 
rac-2b n-Hx/2-PrOH 95/5 3.10 1.29 2.65 
rac-2c n-Hx/2-PrOH 95/5 5.46 1.19 1.75 
rac-2a n-Hx/EtOH 92/8 4.16 1.14 1.41 
rac-2a n-Hx/EtOH 90/10 3.14 1.12 1.43 
rac-2a n-Hx/EtOH 85/15 1.83 1.12 1.25 
rac-2b n-Hx/EtOH 93/7 2.85 1.08 1.00 
rac-2b n-Hx/EtOH 90/10 2.47 1.07 0.60 
rac-2c n-Hx/EtOH 95/5 3.85 1.10 1.15 
rac-2a n-Hx/EtOH/CHCl3 86/9/5 2.55 1.16 2.10 
rac-2a n-Hx/EtOH/CHCl3 88/7/5 3.55 1.17 2.10 
rac-2a n-Hx/EtOH/CHCl3 86/7/7 2.92 1.16 2.36 
rac-2b n-Hx/EtOH/CHCl3 92/4/4 3.71 1.10 1.29 
rac-2b n-Hx/EtOH/CHCl3 88/4/8 2.68 1.12 1.39 
rac-2b n-Hx/EtOH/CHCl3 86/4/10 2.30 1.17 1.59 
rac-2b n-Hx/EtOH/CHCl3 84/4/12 1.86 1.19 1.62 
rac-2c n-Hx/EtOH/CHCl3 93/4/3 4.17 1.14 1.45 
rac-2c n-Hx/EtOH/CHCl3 92/4/4 3.15 1.13 1.38 
a
 Chromatographic conditions on 250 × 4.6 mm ID Chiralpak

 IA column: injection volume: 5 μL, 
samples dissolved in chloroform, flow rate 1 mL/min; UV detection 220 nm with n-Hx/2-PrOH or n-
Hx/EtOH as eluent; 235 nm with n-Hx/EtOH/CHCl3 as eluent for 2b and 2c and 260 nm with n-
Hx/EtOH/CHCl3 as eluent for 2a.  
Tables
Table 2  
Chromatographic data for the resolution of amino acid derivatives rac-2a–c on 
Chiralpak

 IA data working in an overload mode in the analytical column.
Compound Eluent % (v/v) k'  Rs 
rac-2a
a
n-Hx/EtOH/CHCl3 86/7/7 2.67 1.14 1.30 
rac-2b
b
n-Hx/EtOH/CHCl3 84/4/12 2.20 1.19 1.10 
rac-2c
c
n-Hx/EtOH/CHCl3 92/4/4 3.15 1.14 1.15 
a
 Overload mode, c = 25 mg/mL, injection volume: 25 μL, flow rate: 1 mL/min, UV detection 280 nm. 
b
Overload mode, c = 100 mg/mL, injection volume: 10 μL, flow rate: 0.8 mL/min, UV detection 290 nm. 
c
Overload mode, c = 75 mg/mL, injection volume: 10 μL, flow rate: 0.8 mL/min, UV detection 265 nm. 
Tables
Table 3  
Semipreparative resolution of the enantiomers of compounds 2a–c.a
Compound 1
st
 fraction 2
nd
 fraction 3
rd
 fraction 4th fraction
rac-2a
b
100/0 (105 mg) 85/15 (28 mg) 4/96 (72 mg) 0/100 (60 mg) 
rac-2b
c
98.5/1.5 (105 mg) 85/15 (14 mg) 6/94 (41 mg) 0/100 (90 mg) 
rac-2c
d
100/0 (120 mg) 82/18 (33 mg) 3/97 (40 mg) 0/100 (100 mg) 
a
250 × 20 mm ID Chiralpak

 IA column. 
b
 Injection volume: 500 μL, c = 25 mg/mL, flow rate, 18
mL/min; UV detection 280 nm, eluent n-Hx/EtOH/CHCl3 86/7/7. 
c
 Injection volume: 150 μL, c = 150
mg/mL, flow rate, 16 mL/min; UV detection 290 nm, eluent n-Hx/EtOH/CHCl3 84/4/12. 
c
Injection 
volume: 200 μL, c = 75 mg/mL, flow rate, 16 mL/min; UV detection 265 nm, eluent n-Hx/EtOH/CHCl3 
92/4/4. 
Tables
